Who are Brentuximab Vedotin (Bv)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zilovertamab vedotin, Tisotumab Vedotin, LONCASTUXIMAB TESIRINE, Besponsa, Mylotarg, Herceptin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brentuximab-vedotin-bv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Brentuximab Vedotin (Bv) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brentuximab Vedotin (Bv) (Brentuximab Vedotin (Bv)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-drug conjugate (ADC). Area: Oncology.

marketed Antibody-drug conjugate (ADC) CD30 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Brentuximab Vedotin (Bv) (Brentuximab Vedotin (Bv)) — Assistance Publique - Hôpitaux de Paris. Brentuximab vedotin is an antibody-drug conjugate that binds to CD30 on tumor cells and delivers a microtubule-disrupting toxin to induce cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brentuximab Vedotin (Bv) TARGET	Brentuximab Vedotin (Bv)	Assistance Publique - Hôpitaux de Paris	marketed	Antibody-drug conjugate (ADC)	CD30
Zilovertamab vedotin	Zilovertamab vedotin	Merck Sharp & Dohme LLC	phase 3	Monoclonal antibody-drug conjugate	CD30
Tisotumab Vedotin	tivdak	SEAGEN	marketed	Antibody-Drug Conjugate (ADC)	Tissue factor	2021-01-01
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Besponsa	inotuzumab-ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD22	2017-01-01
Mylotarg	Gemtuzumab Ozogamicin	Pfizer	marketed	Antibody-drug conjugate (ADC)	CD33 antigen	2000-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01

Recent regulatory actions (last 90 days)

2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-drug conjugate (ADC) class)

Pfizer · 3 drugs in this class
Jiaxing AnDiCon Biotech Co.,Ltd · 2 drugs in this class
AstraZeneca · 1 drug in this class
BioAtla, Inc. · 1 drug in this class
Byondis B.V. · 1 drug in this class
Charite University, Berlin, Germany · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
Medstar Health Research Institute · 1 drug in this class
OBI Pharma, Inc · 1 drug in this class
On Target Laboratories, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brentuximab Vedotin (Bv) — Competitive Intelligence Brief. https://druglandscape.com/ci/brentuximab-vedotin-bv. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab